Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As AbbVie's Risankizumab Looms, Sun Pushes To 'Maximize Time' Of Ilumya

Executive Summary

Sun says that it is "excited" with Ilumya’ s initial launch uptake in the crowded US psoriasis segment, but is pushing ahead with "speedy execution" of plans for the product before the potential arrival of new rivals such as AbbVie’s same-class therapy risankizumab.

You may also be interested in...



Sun’s Ilumya Ramps Up In Skyrizi’s Shadow

Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian firm said that the arrival of AbbVie’s rival Skyrizi hasn’t adversely impacted its formulary position.

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.

Sun’s Ilumya Gnaws At US Psoriasis Market

Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel